Presentation is loading. Please wait.

Presentation is loading. Please wait.

REVOLUTiONiZiNG MALARiA VACCiNATiON

Similar presentations


Presentation on theme: "REVOLUTiONiZiNG MALARiA VACCiNATiON"— Presentation transcript:

1 REVOLUTiONiZiNG MALARiA VACCiNATiON
Photo credit:: PATH Malaria Vaccine inniciative

2 Company Founders Business development advisors

3 Support 100 thousand US$ 1.2 million US$ 320 thousand US$
Phase I funding 100 thousand US$ (November 2010) Phase II funding 1.2 million US$ (November 2013) Supplement to 320 thousand US$ (December 2014) Pre-clinical safety studies 280 thousand US$ (February 2016)

4 Problem MALARIA 2.5 billion people at risk of contracting malaria 700 thousand deaths every year 12 billion US$ in lost GDP of endemic countries NO EFFECTIVE VACCINE AVAILABLE Most advanced candidate only affords ~36% protection against a single parasite species Photo credit: Antonio M. Mendes

5 4.5 billion US$ global market
Market potential 4.5 billion US$ global market Humanitarian market: (estimated value: 3 billion US$) Private market: (estimated value: 700 million US$) Tourist & military market: (estimated value: 800 million US$) Photo credit: NYtimes

6 Whole organism vaccines
Vaccine Approaches Whole organism vaccines Shown to confer >90% sterile protection against a new infection in Phase I/IIa trials Serious safety concerns Extremely high dosages Do not target the most prevalent parasite, P. vivax Mandatory high biosafety BSL3 production facilities

7 WHOLE-ORGANISM PLATFORM FOR VACCINATION AGAINST
Uniqueness Plasmodium berghei A SAFE & VERSATILE WHOLE-ORGANISM PLATFORM FOR VACCINATION AGAINST MULTIPLE HUMAN PARASITES Photo credit: worldnaturephoto.com

8 Pre-clinical data

9 Stakeholders

10 New Vaccine Candidates
Capable of blocking parasite development at various stages of their life cycle

11 Production & delivery Establishment of
cell culture-based production of sporozoites Development of a vaccine cryopreservation system

12 Cryopreservation system

13 Cell-culture-based production of sporozoites
400 300 200 100 3 5 10 12 15 18 21 25 Time (days) Luminescence (% of d0) d10 d3 d12 d5 d21

14 Strategy Vaccine Clinical Development (Market entry: 2025)
Production & delivery technology (Market entry: 2018)

15 LET’S PUT AN END TO MALARiA Photo credit: Antonio M. Mendes


Download ppt "REVOLUTiONiZiNG MALARiA VACCiNATiON"

Similar presentations


Ads by Google